Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort

Lumley SF. et al, (2025)

Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field

Lumley SF. et al, (2025), The Lancet Microbe, 101076 - 101076

Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms

Lumley SF. et al, (2025), Scientific Reports, 15

A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir

Lumley SF. et al, (2024), Journal of Clinical Virology, 174, 105711 - 105711

Corrigendum to A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.: Journal of Clinical Virology 174 (2024) 105711.

Lumley SF. et al, (2024), Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 174

Whole genome sequencing of hepatitis B virus (HBV) using tiled amplicon (HEP-TILE) and probe-based enrichment on Illumina and Nanopore platforms

Lumley SF. et al, (2024)

Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy

Lumley S. et al, (2024), Sexually Transmitted Infections, 100, 329 - 331

Peer support for people living with hepatitis B virus—A foundation for treatment expansion

Downs LO. et al, (2024), Journal of Viral Hepatitis, 31, 490 - 499

Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?

Im YR. et al, (2024), Sexually Transmitted Infections, 100, 259 - 263

Hepatitis B Core Related Antigen - Does it meet our expectations? Evidence from Cohorts in the United Kingdom and South Africa

Downs LO. et al, (2024)

Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny

Hunt M. et al, (2024)

HEP-TILE: HBV whole genome sequencing (nanopore protocol) v1

Lumley S. et al, (2024)

HEP-TILE: HBV whole genome sequencing (nanopore protocol) v2

Lumley S. et al, (2024)

Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection

Delphin M. et al, (2024), The Lancet Gastroenterology & Hepatology, 9, 383 - 392

A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) genotypic resistance in people treated with entecavir or tenofovir

Lumley SF. et al, (2023)

Evaluation of sequence hybridization for respiratory viruses using the Twist Bioscience Respiratory Virus Research panel and the OneCodex Respiratory Virus sequence analysis workflow

Kapel N. et al, (2023), Microbial Genomics, 9

Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients

Beckett J. et al, (2023)

Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing

Lumley SF. et al, (2023)

Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2022), JCI Insight, 7

Load More

Include forthcoming?

	
		OSZAR »